(P145) Application of Perfusion SPECT Image-Guided Planning and Clinical Outcomes in Locally Advanced Lung Cancers

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

The clinical effect of perfusion single-photon emission computed tomography (SPECT) image-guided planning in patients treated for locally advanced and metastatic lung cancers is assessed.

Jonathan W. Thompson, MD, Sui Shen, PhD, Luvenia Bender, MD, Sharon A. Spencer, MD; Department of Radiation Oncology, University of Alabama, Birmingham

Purpose: To assess the clinical effect of perfusion single-photon emission computed tomography (SPECT) image-guided planning in patients treated for locally advanced and metastatic lung cancers.

Methods: Seventeen patients with lung cancer who had perfusion imaging obtained in the treatment position fused with treatment planning scans were evaluated to assess the effects of radiation to regions of perfusion, as defined by the pixelated value of the perfusion image (PVPI) method. This method created regions of perfusion, defined as full perfusion (P60–100), moderate perfusion (P40–60), poor perfusion (P20–40), and very poor perfusion (P0–20). All patients were planned prospectively at the time of treatment, with the intent of avoidance of actively perfusing lung while respecting known parameters associated with increased risk of pneumonitis. Volumes of each perfusion region were recorded in all patients, and ratios of planning target volume (PTV) to total lung and active lung were generated. Values for V20, V5, and mean lung dose (MLD) were recorded for whole lung as well as in each perfusion region. Dosimetric variables in each perfusion region were recorded, and patients were retrospectively evaluated for the development of radiation pneumonitis.

Results: Five patients required systemic steroids for radiation pneumonitis. There were no significant differences in pretreatment pulmonary function tests (PFTs); dose delivered; PTV volume; or whole-lung V20, V5, or MLD between patients who did and did not require systemic steroids for pneumonitis. There was a trend for less volume of P60–100 in those with pneumonitis (171 cc vs 273 cc; P = .1). There were a number of differences noted in P20–40 with regard to trends of increased V20 (28% vs 23%; P = .1) and V5 (59% vs 47%; P = .1) in patients with pneumonitis. There was also a statistically significant increase in MLD in P20–40 (1,696 cGy vs 1,357 cGy; P = .04) as well as V5 in P40–60 (63% vs 40%; P = .05). In patients who developed pneumonitis, there was a trend for a decreased ratio of P60–100 to PTV (0.41 vs 1.98; P = .09). Of the six patients who were treated using IMRT, there were statistically significant increases in V5 (61% vs 48%; P = .05) in the whole lung as well as increases of V20 in P0–20 (23% vs 33%; P = .02) and P20–40 (19% vs 27%; P = .03).

Conclusion: SPECT-based perfusion imaging has utility in terms of functional treatment planning for lung cancer and may assist with avoidance of actively perfusing lung, although the clinical significance of this remains in question due to results suggesting some predictability of pneumonitis associated with higher doses delivered to poorly perfusing regions. Since treatment plans were designed with the intention of minimizing dose to the active regions and thereby pushing this dose to regions of lower perfusion, it can be inferred that the avoidance of highly perfusing regions may make moderately perfusing regions more vulnerable to the effects of radiation pneumonitis, especially in patients with small volumes of active lung. With the advantage of increased conformity, IMRT has utility in avoidance of these concerning regions and is a subject of ongoing research.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
Related Content